+86-571-85081802     info@multin.cn
Anti-inflammatory Drugs /CAS:151767-02-1/Montelukast Sodium Montelukast Intermediate
Home » Products » Pharmaceutical » Anti-inflammatory Drugs /CAS:151767-02-1/Montelukast Sodium Montelukast Intermediate

Contact Us

 Tel: +86-571-85081802
  Phone: +86-13655719091
 E-mail: info@multin.cn
  Add: Room 321,lingjun Mansion South,the 10th Chaowang Road,xiacheng District,hangzhou City,zhejiang Province China

Anti-inflammatory Drugs /CAS:151767-02-1/Montelukast Sodium Montelukast Intermediate

Share to:

Product Name: Montelukast Sodium
Appearance: White Powder
CAS: 151767-02-1
MF: C35H35ClNNaO3S
MW:608.17
Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor

  • Cas:151767-02-1
  • MT
  • 151767-02-1
  • 151767-02-1

Anti-inflammatory drugs /CAS:151767-02-1/Montelukast sodium Montelukast Intermediate

 151767-02-1 price

Molecular Formula: C35H35ClNO3S.Na 

Molecular Weight: 608.17 

CAS No.: 151767-02-1

API of anti-asthma drug. Also it is used in the treatment of seasonal transformation reactions, and PAR. 

Appearance: White crystalline powder

Content: 98% by HPLC

 

Product Name

Stock Montelukast sodium CAS 151767-02-1

CAS No.

151767-02-1

Category

 API

Quality Standard

EP/USP

MSDS

Available

COA

Contact with Senwayer for updated version COA.

Sample

Available

MOQ

1kg

Delivery Date

Within three days after payment

Place Of Origin

China

Application

Pharmaceutical raw materials

 

                                   


111

Introduction:


Product Name: Montelukast Sodium
Appearance: White Powder
CAS: 151767-02-1
MF: C35H35ClNNaO3S
MW:608.17
Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific mechanism of action, it does not interact with other asthma medications such as theophylline.Another leukotriene receptor antagonist is zafirlukast (Accolate), taken twice daily. Zileuton (Zyflo), an asthma drug taken four times per day, blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.

Function

Montelukastis a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.Montelukast comes as a tablet, a chewable tablet, flash tablet and granules to take by mouth.Montelukast is usually taken once a day with or without food.Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

Application:

Montelukast is used for a number of conditions including asthma, exercise induced bronchospasm, allergic rhinitis, primary dysmenorrhoea and urticaria. It is mainly used as a complementary therapy in adults in addition to inhaled corticosteroids, if they alone do not bring the desired effect. It is also used to prevent allergic reactions and asthma flare-ups during the administration of intravenous immunoglobulin.



Packing and Shipping:


packing

packing1


OUR PRODUCTS

HOT LINKS

Copyright  2020 ZHEJIANG MULTINPHARMA CO.,LTD All Rights Reserved  浙ICP备17013806号-1  |  Technology by www.leadong.com